Category Archives: Biotechnology

With five U.S. patents issued and dozens more filed and pending around the world, On Target Laboratories LLC is working to advance its revolutionary fluorescent imaging technology that could help surgeons pinpoint and remove more cancerous tissues than has ever been possible while preserving more healthy tissue for patients. Headquartered at Purdue Research Park of West Lafayette, the company is developing a series of molecules, which, when administered intravenously, show promise in targeting many types of cancer cells, said Dr. Sumith Kularatne, On Targets vice president of research and development. In addition to our current U.S. patents, we have 11 more either filed or pending in the U.S., Kularatne said. We have another 33 patents pending worldwide. These patents are very important in helping us move our discoveries to the public where they can help people. These molecules carry a fluorescent dye and target diseased cells, including cancer, enabling surgeons to better diagnose and remove the disease while avoiding collateral damage to healthy tissue such as nerves. OTL38 is a novel compound consisting of a folic acid-targeting molecule, or ligand, linked to a near-infrared dye. Following current clinical trial protocols, OTL38 is injected two hours before surgery and is intended … Continue reading →

Cellect Biotechnology Ltd. (NASDAQ: APOP) Cellect Biotechnology is having an incredibly strong day in the market today. As soon as the session opened, the stock was already trading on overwhelmingly impressive gains. From there, we've seen a continuation of strong movement. Below, we'll talk about what we're seeing from the stock, why, and what we'll be watching for with regard to APOP ahead. As mentioned above, Cellect Biotechnology is having an incredibly strong day in the market today. At the opening bell, the stock was already trading well into the green. Throughout the morning, we've seen a continuation of gains. At the moment (10:52), APOP is trading at $6.91 per share after a gain of $1.08 per share (18.52%) thus far today. As is almost always the case, our partners at Trade Ideas were the first to send the alert that APOP was making a run for the top. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. It didn't take long to uncover the story. The gains are ultimately the result of a positive data release. Early this morning, Cellect Biotechnology released positive results from its clinical … Continue reading →

The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016, posting a loss of more than 20%, has started posting gains again, and is looking like the rally may be poised to continue. The biggest play in the sector, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), is up more than 10% on the year (its smaller equal weight counterpart, the SPDR S&P Biotech ETF (NYSEARCA:XBI), is up over 17%). The sector has alternatively gotten good and bad news from the White House. For many months, there has been talk of lowering drug prices through open competition or price caps putting pressure on the big drug manufacturers. On the other hand, President Trump spoke recently of his desire to reform the entire drug approval process in order to "speed the approval of life-saving medications" and "cutting the red tape at the FDA." That notion was welcomed by the equity markets even though it received a tepid response from big pharma companies. One thing working in favor of biotech right now is M&A and the big prize could be Bristol-Myers … Continue reading →

Market Summary Follow Puma Biotechnology Inc is a A biopharmaceutical company PBYI - Market Data & News PBYI - Stock Valuation Report Puma Biotechnology Inc (PBYI) traded on unusually high volume on Feb. 21, as the stock lost 4.72% to close at $38.35. On the day, Puma Biotechnology Inc saw 1.1 million shares trade hands on 8,009 trades. Considering that the stock averages only a daily volume of 715,433 shares a day over the last month, this represents a pretty significant bump in volume over the norm. Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances. The stock has traded between $73.27 and $19.74 over the last 52-weeks, its 50-day SMA is now $34.44, and its 200-day SMA $41.65. Puma Biotechnology Inc has a P/B ratio of 15.46. Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Headquartered in … Continue reading →

February 20, 2017 6:42am NASDAQ:IBB The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016 posting a loss of more than 20%, has started posting gains again and is looking like the rally may be poised to continue. The biggest play in the sector, the iShares Nasdaq Biotechnology ETF (IBB), is up more than 10% on the year (its smaller equal weight counterpart, the SPDR S&P Biotech ETF (XBI), is up over 17%). The sector has alternatively gotten good and bad news from the White House. For many months, there has been talk of lowering drug prices through open competition or price caps putting pressure on the big drug manufacturers. On the other hand, President Trump spoke recently of his desire to reform the entire drug approval process in order to speed the approval of life-saving medications and cutting the red tape at the FDA. That notion was welcomed by the equity markets even though it received a tepid response from big pharma companies. One thing working in favor of biotech right now is M&A and the … Continue reading →

By: Express News Service | Mohali | Published:February 19, 2017 4:43 am The National Agri-Food Biotechnology Institute, Mohali, on Saturday observed its 7th foundation day. The National Agri-Food Biotechnology Institute, Mohali, on Saturday observed its 7th foundation day at the NABI premises at Phase 8 in Mohali. The NABI is an autonomous institute aided by the department of Biotechnology, Government of India, and carries out research in the area of biotechnological applications at the intersection of agriculture, food and nutritional biotechnology. Watch what else is making news: A gathering of heads of the institutes and faculty from the Tricity region joined the function. More than 200 scientists, students and staff participated in the foundation day ceremony. Prof. Nagendra Kumar Singh, national professor, B P Pal chair and project director, ICAR National Research Centre on Plant Bioterchnology, New Delhi was the chief guest. He delivered the foundation day lecture on Decoding the genomes of crop plants uniquely important for India. Dr T R Sharma, executive director, NABI highlighted the achievements of NABI and mentioned that NABI is poised to play an important role in generating world-class knowledge in the area of agri-food and health security. NABI is working on strategies to … Continue reading →

Market Summary Follow Puma Biotechnology Inc is a A biopharmaceutical company PBYI - Market Data & News PBYI - Stock Valuation Report Puma Biotechnology Inc (PBYI) had a good day on the market for Friday February 17 as shares jumped 7.76% to close at $40.25. About 1.37 million shares traded hands on 9,969 trades for the day, compared with an average daily volume of 928,303 shares out of a total float of 36.82 million. After opening the trading day at $37.25, shares of Puma Biotechnology Inc stayed within a range of $40.50 to $36.70. With today's gains, Puma Biotechnology Inc now has a market cap of $1.48 billion. Shares of Puma Biotechnology Inc have been trading within a range of $73.27 and $19.74 over the last year, and it had a 50-day SMA of $34.47 and a 200-day SMA of $41.58. Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Puma Biotechnology Inc is based out of Los Angeles, CA and has some 156 employees. Its CEO is Alan H. Auerbach. For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report … Continue reading →

CHATSWORTH, CA / ACCESSWIRE / February 15, 2017 / Cavitation Technologies, Inc. (CTi) (OTCQB: CVAT) (Berlin:WTC) and CBDual Biotechnology Corp announced today that the two companies have reached a comprehensive cross-licensing agreement. This agreement covers intellectual property involving application of technology and process patents to produce high quality pharmaceutical grade cannabis materials. The patented technology facilitates the production of cannabinoid formulations that may include Cannabidiol (CBD) and Tetrahydrocannabinol (THC) that can be easily mixed into fluids or medications providing increased stability of products and a much quicker enhanced absorption rate of medications. Dr. Greg Rubin, CEO of CBDual Biotechnology Corp. commented, "The cannabis derived products market is growing rapidly in North America. Market Research Future reports indicate that U.S., Canada, and Mexico are dominant markets for cannabis products and these markets are expected to grow at 33% per annum from 2016 to 2021. Growing awareness about cannabis medicinal properties is also reflected in growing demand for new CBD based products. The development of consumer and medical products require the development of the best quality and utilization of the most innovative technologies in order to achieve ultimate results. This is only possible if we use the most advanced technological processes and … Continue reading →

Biotechnology The Degree Associate in Science (A.S.) From altering the genetic information of plants and animals to producing cells to create pharmaceutical products, the science of biotechnology is using cutting-edge technology and the basic ingredients of life to benefit society. Through the biotechnology degree program at FLCC, you will participate in what many consider to be the most important applied science of the 21st century. Career opportunities in biotechnology are diverse and intriguing. Areas that are explored include: According to the Occupational Outlook Handbook, employment of biological technicians is expected to grow 10 percent from 2012 to 2022, about as fast as the average for all occupations. The A.S. Biotechnology degree program is designed to prepare you for transfer into a four-year institution as a biotechnology or biology major. Additionally, our hands-on approach to supporting the development of a suite of laboratory skills will prepare you for entrance into the job market. Skills and Methods: Courses in the program focus on skill development in the following areas: Facilities: Facilities for the program include a fully equipped biotechnology lab, extensive spectrophotometric resources, cell culture and cryogenic equipment, electrophoresis equipment, high and low pressure liquid chromatography, and a 3L and 5L bioreactor … Continue reading →

February 17, 2017 6:33am NASDAQ:IBB NYSE:XLV From Taki Tsaklanos: Biotechnology was once the darling of stock market investors. Not so anymore, since the summer of 2015 the sector collapsed from 400 points to 250 points in the IBB ETF. Likewise, the health stock market sector lost its status of outperformer as the XLV ETF went from 75 points to 62 points. Note that biotech is part of the health sector (XLV). Biotechnology is now showing the first signs of life. The IBB ETF is up 3 percent on the week. We warned readers to watch closely the 250 level in this alert: Biotechnology and Health Sector Testing Long Time Support. Later on, we noticed that biotech refused to break down, and started to show a pattern of higher lows. Right now, the biotech stock market sector is testing a breakout level. Things will really get bullish once 300 points in the IBB ETF is cleared. The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) fell $1.78 (-0.61%) in premarket trading Friday. Year-to-date, IBB has gained 10.40%, versus a 5.01% rise in the benchmark S&P 500 index during the same period. IBB currently has an ETF Daily News SMART Grade of A (Strong … Continue reading →